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Background: We have shown previously that some calcium antagonists inhibit hyaluronan export, loss of
proteoglycans, and degradation of collagen from osteoarthritic cartilage. Clinically approved calcium antagonists
normally are prescribed for cardiac arrhythmia. In the present study, we compared the effect of these drugs on
osteoarthritic patients which had received no medication and patients which were also diagnosed for cardiac
arrhythmias and were treated with calcium antagonists. The effects and the side effects of the used drugs were
analyzed.
Method: We used the Lequesne questionnaire to examine patients with osteoarthritis (212 patients, control group
receiving no calcium antagonists) and patients with cardiac arrhythmia and osteoarthritis (188 patients treated with
various calcium antagonists). The answers of the questionnaires were transformed into the Lequesne scoring
system quantifying the severity of the disease. The Lequesne score is a standardized questionnaire focused on
osteoarthritis. It is a 24-scale questionary in which low scores indicate low functional activity.
Results: The data showed that the mean score of the control group (6.2) was higher than the treated group (5.2),
the drugs differed in their efficiency. Verapamil had a slightly worse score and Azupamil, Escor, Felodipine, and
Nifedipine showed no alteration. Adalat, Amlodipine, Carmen, Nitrendipin, and Norvasc lead to an improvement.
Conclusion: These results suggest that inhibition of hyaluronan export may have a beneficial effect on human
osteoarthritis.
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Osteoarthritis (OA) is the most common specific joint
disease in humans and the largest cause of chronic dis-
ability in the elderly [1]. It occurs when the equilibrium
between breakdown and repair of the joint tissues be-
comes unbalanced. There are currently no pharmaco-
logical interventions available to patients for modifying
the underlying disease in spite of intensive research over
the past five decades [2,3]. Previously, it was thought
that proteolytic degradation of collagen and aggrecan
was primarily responsible for cartilage breakdown. Ef-
forts to develop protease inhibitors led to compounds* Correspondence: Kraj@gmx.net
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unless otherwise stated.that were chondroprotective in vitro and in animal
models, but results from clinical trials were equivocal
[4]. However, increased hyaluronan synthesis precedes
the stimulation of protease synthesis [5,6]. When we dis-
covered that hyaluronan was exported by the multidrug
resistant protein MRP5, a whole series of hyaluronan ex-
port inhibitors were suddenly available that we conse-
quently tested for their effects on osteoarthritic reactions
of chondrocytes in culture, on bovine cartilage explants,
and in a rat model of osteoarthritis [7-10]. The hyaluronan
export inhibitors tested effectively reduced not only hya-
luronan export but also subsequent osteoarthritic reac-
tions such as proteoglycan loss and collagen degradation.
Some of the drugs were approved calcium antagonists
prescribed for cardiac arrhythmia.al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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some process, we analyzed here the potential of several
drugs to ameliorate the symptoms of osteoarthritis in
patients which suffered from cardiac arrhythmias and
were treated with the calcium antagonists and compared
the data with patients which solely had osteoarthritis.
The study was carried out in accordance with the
World Medical Association Declaration of Helsinki.
Materials and methods
The Lequesne questionnaire [11] was modified to in-
corporate the patient’s weight and height. The Lequesne
score is a standardized questionnaire focused on osteo-
arthritis. It is a 24-scale questionary in which low scores
indicate low functional activity (Table 1).
It was answered by 400 patients with osteoarthritis
(207 women and 193 men). More than 99% of the pa-
tients were older than 50 years. Both the control and the
active treatment groups have been diagnosed for osteo-
arthritis for more than 1 year before and the active treat-
ment group has received calcium antagonists for more
than 1 year.
Pre-study calculations revealed that 198 patients for
each group were required to arrive at a statistical signifi-
cance of p < 0.05 and a power of 80% for a difference in
one unit in the Lequesne score. Matched pairs were
established for potential interference variables such as
gender, age, and body mass index. The first evaluations
of equivalences were performed stepwise with 100, 200,






Adalat® (Nifedipine) 4.0 5 3 0
Amlodipine®
(Amlodipine)
3.5 22 2.97 0
Azupamil®
(Verapamil)
6 8 3.59 0
Carmen®
(Lercanidipine)
3 21 2.91 0
Escor® (Nilvadipine) 6 5 4.72 0
Felodipine®
(Felodipine)
5 7 4.1 0
Nifedipine®
(Nifedipine)
6.2 15 5.21 0
Nitrendipine®
(Nitrendipin)
2.1 8 2.8 0
Norvasc®
(Amlodipine)
4.8 48 5 0
Verapamil®
(Verapamil)
6.9 49 5 0
Control group 6.2 212 4.85 0
SD standard deviation.could not be achieved for gender (55% women in the ac-
tive treatment group and 45% women in the control
group) and body mass index (76.27 ± 9.1 kg in the con-
trol group).
The Lequesne score correlates significantly with pain
and consists of three subscores which were calculated
individually and together: pain and discomfort, max-
imum distance walked, and activities of daily living with
a maximum score of 8 for each subscore and a total
score of 24 (see Additional file 1). A difference in one
score unit is regarded as clinically relevant. The groups
were evaluated by the Levene test for equality of vari-
ance and by the T-test for equality of the mean.
Results
In addition to the calcium (Ca) antagonists analyzed pre-
viously for inhibition of hyaluronan export, we included
here those compounds that were currently used as medi-
cations. Furthermore, we found a slight drift concerning
the inhibitory concentrations for hyaluronan which were
in the micromolar range, whereas the Ca antagonists
were supposed not to inhibit hyaluronan through alter-
ations of the intracellular Ca2+ concentration but rather
by direct interaction with the hyaluronan exporter
MRP5.
Correlation of export inhibition and statistics
The total Lequesne score and the three subscores were
calculated for 188 patients in the active treatment group
and 212 patients in the control group (Table 2). The
total Lequesne score showed a significant difference of
the active treatment group versus the control group.
This significance was mainly found in subgroups 2 and 3
for the maximum walking distance and activities of daily
living, respectively, whereas the difference in subgroup 1
for pain and discomfort was insignificant.Table 2 Total and subgroup Lequesne score
Group Mean SD p value
Total
Active treatment 5.23 1.89 0.044
Control 6.19 1.57
Subgroup 1
Active treatment 1.64 1.73 0.607
Control 1.73 1.84
Subgroup 2
Active treatment 1.72 1.84 0.044
Control 2.08 2.06
Subgroup 3
Active treatment 1.87 5.23 0.008
Control 2.38 6.19
SD standard deviation.
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drugs versus the control group. Only those groups with
five or more patients were incorporated. Significant ameli-
oration of the Lequesne score was found for Amlodipine®,
Carmen®, and Nitrendipine®. It is noteworthy that the
difference for the amlodipine-containing drug Norvasc®
was not significant.
Discussion
The present paper describes that Ca antagonists inhibit
hyaluronan export by MRP5 which is the principle hyalur-
onan exporter for fibroblasts and chondrocytes and they
simultaneously improved the Lequesne score for osteo-
arthritis. There were gross differences in their activities.
Since the effective concentrations as Ca antagonists were
order of magnitude lower that the inhibitory concentra-
tion for hyaluronan export inhibition, the beneficial effect
on human osteoarthritis could not be mediated by direct
with the exporter, because the high concentration for hya-
luronan export inhibition will never be reached by drug
treatment. Therefore, the action must rely in another yet
unknown mechanism.
If the Ca antagonists give rise to such diverse re-
sponses in the Lequesne score as found in our results, it
cannot rely on a common biochemical mechanism of
modulating the Ca concentration. The responses must
thus be attributed to the special structure of the individ-
ual compounds.
It was calculated initially that a patient number of 198
is required to allow a statistically significant conclusion.
This calculation should also apply for the individual
compounds. However, the large deviations of some com-
pounds in the Lequesne score from the control were
based on less than 10 patients. Thus, this figure should
not be regarded as significant.
Although the results for single drugs were not signifi-
cant, the overall effect of Ca antagonists on OA patients
as compared to controls may nevertheless indicate an
underlying biochemical mechanism. We recently discov-
ered that hyaluronan export by MRP5 is dependent on
concurrent K+ efflux through Kir channels [12].
The Kir channels belong to the calcium-activated K+
channels [13]. Thus, blockage of calcium entry into the
cytoplasm may inhibit K+ efflux and, simultaneously,
also excessive hyaluronan export. If this scenario is valid,
treatment of OA patients with hyaluronan-inhibiting
drugs may be beneficial.
There are several limitations to the current analysis
that must be taken into account when analyzing these
results. Firstly, although a control arm was offered as
means of a comparison, there were notable differences
in the demographics between the groups. The fact that
we deal with a heterogenous group of Ca antagonists
leads to an unknown range of bias. It is possible thatthese factors influenced the overall results. The fact that
we did not perform a power analysis and that we did not
randomize the patients should be stated as a major limi-
tation of the present study. Furthermore, the present
study deals with patients who suffered on OA; that
means that they could suffer also from pain caused by
other joints which could be affected. Another reason
could be that the patients were affected positive or nega-
tive by other co-medication.
Conclusion
Taken together, the presented results indicate that Ca
antagonists might be efficient in preventing progression
of osteoarthritis. However, in the absence of randomized
clinical trial data, the use of the drug cannot be justified
yet. Hence, data from a randomized study are needed to
better elucidate the potential of Ca antagonists in pre-
venting progression of osteoarthritis.
Additional file
Additional file 1: Index of Severity for Osteoarthritis of the Knee by
Lequesne et al. Lequesne et al. developed an index of severity for
osteoarthritis for the knee (ISK). This can be used to assess the
effectiveness of therapeutic interventions.
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